Thin on detail, UK-US trade agreement is a first step, says ABPI

9 May 2025

The UK government has announced a trade agreement with the USA. The UK-US Economic Prosperity Deal was agreed on Thursday May 8 with further details released on Friday May 9.

Responding to the development, Richard Torbett, chief executive of the trade group Association of the British Pharmaceutical Industry (ABPI), said: “We thank the government for its continued efforts that have led to this essential first-step agreement with the US.”

Although pharma was not mentioned at all as US President Donald Trump and UK Prime Minister Keir Starmer unveiled the 'agreement in principle', as it was described by the office of the US Trade Representative (USTR).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK